Herantis Pharma Plc | Company Release | November 15, 2023 at 20:25:00 EET
The following members have been appointed to Herantis Pharma's Shareholders' Nomination Committee:
- Kyösti Kakkonen, representing Joensuun Kauppa ja Kone Oy (Chair),
- Pia Gisgård, representing Swedbank Robur,
- Timo Syrjälä, representing himself and Acme Investments SPF S.à.r.l., and
- Timo Veromaa, the Chair of Herantis Pharma's Board of Directors.
Herantis Pharma's Shareholders' Nomination Committee consists of four members, of which three represent the Company's shareholders. The Chair of Herantis Pharma's Board of Directors will serve as the fourth member of the Nomination Committee.
The Shareholders' Nomination Committee prepares and presents to the Annual General Meeting proposals on the remuneration, number and members of the Board of Directors.
For more information, please contact:
Julie Silber/Gabriela Urquilla
Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19
Email: ir@herantis.com
Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225
About Us
About Herantis Pharma Plc
Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096, is an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. It combines the compelling mechanism of action of CDNF with the convenience of subcutaneous administration. A Phase 1a clinical trial has demonstrated a good safety and tolerability profile, and efficient blood-brain barrier penetration of subcutaneously administered HER-096 in humans.
The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.
Company website: www.herantis.com